Savara (SVRA) said Thursday it has launched its aPAP ClearPath dried blood spot test in the US.

The test is designed to help obtain a diagnosis of aPAP, a rare autoimmune lung disease, through a finger-prick blood sample, the company said.

The DBS test has achieved 100% sensitivity and specificity in a group of individuals with aPAP autoantibody status, Savara said.

Shares were almost 2% higher in recent premarket activity.